While AML is considered a rare disease overall, the sobering reality that it strikes an estimated 20,380 people in the US each year makes its profound impact undeniable.
Key Takeaways
- Approximately 20,380 new cases of AML diagnosed in the US in 2023
- AML accounts for about 1.3% of all new cancer cases in the US
- Median age at diagnosis for AML is 68 years
- Prior chemotherapy exposure increases AML risk 10-fold
- Smoking doubles AML risk in heavy smokers
- Radiation exposure (e.g., atomic bomb survivors) raises AML risk 10-50x
- Fatigue is the most common symptom in 90% of AML patients
- Anemia present at diagnosis in 85-90% of cases
- Bone marrow blasts ≥20% defines AML diagnosis
- Induction chemotherapy CR rate 60-80% in young patients
- 7+3 regimen (cytarabine + daunorubicin) standard for fit patients
- Venetoclax + HMA CR/CRi 67% in unfit elderly
- 5-year survival 10-20% over age 65
- Favorable cytogenetics: 5-year OS 50-70%
- Adverse risk: median OS 8-12 months
AML is a rare but serious cancer primarily affecting older adults, with over 20,000 new U.S. cases annually.
Incidence and Prevalence
1Approximately 20,380 new cases of AML diagnosed in the US in 2023
Verified2AML accounts for about 1.3% of all new cancer cases in the US
Verified3Median age at diagnosis for AML is 68 years
Verified4Incidence rate of AML is 4.1 per 100,000 men and women per year based on 2017–2021 data
Directional5AML is the most common acute leukemia in adults
Single source6Globally, there were about 147,000 new AML cases in 2020
Verified7AML incidence increases with age, peaking after 65 years
Verified8In children, AML represents 15-20% of all leukemias
Verified9US death rate for AML is 2.7 per 100,000 men and women per year
Directional10AML comprises 80% of acute leukemias in adults
Single source11Lifetime risk of developing AML is 0.5% (1 in 200)
Verified12Annual incidence in Europe is about 3.7 per 100,000
Verified13AML incidence in Japan is lower at 2.4 per 100,000
Verified14Prevalence of AML in US adults over 65 is higher than younger groups
Directional155-year relative survival for all AML stages is 31.9%
Single source16AML represents 1.2% of all leukemia cases
Verified17Incidence in African Americans is 4.5 per 100,000 vs 4.0 in whites
Verified18Pediatric AML incidence is 0.9 per 100,000 children
Verified19AML cases in US men: 11,300 annually
Directional20AML cases in US women: 9,080 annually
Single source21Global AML mortality was 111,000 in 2020
Verified22AML incidence rose 3% annually from 2001-2019 in some regions
Verified231.8% of cancer deaths in US are from AML
Verified24AML is rare under age 40
Directional25SEER data shows 10,550 deaths from AML in 2021
Single source26AML accounts for 0.9% of all new cancer cases and deaths
Verified27Incidence higher in Hispanics at 4.3 per 100,000
Verified28AML in adolescents/young adults: 1.1 per 100,000
Verified2980-90% of AML cases occur in adults over 60
Directional30AML smoking-attributable fraction is 18%
Single sourceIncidence and Prevalence Interpretation
While AML may be a statistical rarity overall, it's a devastatingly common foe for adults over 60, claiming its highest toll just as many are looking forward to retirement, with a survival rate that underscores the urgent need for progress.
Risk Factors and Causes
1Prior chemotherapy exposure increases AML risk 10-fold
Verified2Smoking doubles AML risk in heavy smokers
Verified3Radiation exposure (e.g., atomic bomb survivors) raises AML risk 10-50x
Verified4Down syndrome increases AML risk 10-20 times
Directional5Benzene exposure risk ratio for AML is 1.4-3.8
Single source6Myelodysplastic syndromes (MDS) precede 30% of AML cases
Verified7Obesity associated with 20-40% increased AML risk
Verified8Family history increases risk 2-4 fold in relatives
Verified9TP53 mutations found in 30% of therapy-related AML
Directional10Male gender has 25% higher AML incidence than females
Single source11Fanconi anemia patients have 500-1000x AML risk
Verified12Chronic myelomonocytic leukemia (CMML) progresses to AML in 15-30%
Verified13Pesticide exposure OR=1.2-2.0 for AML
Verified14Age over 65 is strongest risk factor, RR>10
Directional15Genetic syndromes like Klinefelter increase risk 4x
Single source16Topoisomerase II inhibitors cause 25% of therapy-related AML
Verified17Alcohol consumption >45g/day increases risk by 22%
Verified18RUNX1 mutations in 10-15% familial AML cases
Verified19Hairy cell leukemia transformation to AML rare, <1%
Directional20Solvent exposure meta-analysis OR=1.3 for AML
Single source21CEBPA mutations in 10% de novo AML, hereditary form rare
Verified22Prior Hodgkin lymphoma treatment: 1-5% develop AML
Verified23GATA2 germline mutations cause 15% familial MDS/AML
Verified24Arsenic exposure in water linked to 1.5x AML risk
Directional25DOCK8 deficiency: 20% develop AML
Single source26Alkylating agents cause 50-70% therapy-related AML
VerifiedRisk Factors and Causes Interpretation
The unsettling résumé for acute myeloid leukemia reveals it is an opportunistic disease that preys on both the profound vulnerabilities of genetics and the accumulated insults of modern life, from workplace toxins to medical treatments themselves.
Survival Rates and Prognosis
15-year survival 10-20% over age 65
Verified2Favorable cytogenetics: 5-year OS 50-70%
Verified3Adverse risk: median OS 8-12 months
Verified4NPM1 mutated without FLT3-ITD: 5-year OS 60%
Directional5FLT3-ITD high allelic ratio: 5-year OS <20%
Single source6ELN 2022 favorable risk: 5-year survival 60%
Verified7Core binding factor AML: 5-year OS 70%
Verified8TP53 mutated: median OS 5 months
Verified9Post-HSCT relapse-free survival 50% at 3 years
Directional10Pediatric AML 5-year survival 70%
Single source11Secondary AML median OS 8 months
Verified12MRD negative post-induction: OS doubled
Verified13Age <60 favorable: 5-year OS 40-50%
Verified14Complex karyotype (>3 abnormalities): OS <10% at 5 years
Directional15Intermediate risk 5-year OS 30-40%
Single source161-year survival overall 38%
Verified17Monosomal karyotype: 4% 5-year survival
Verified18IDH1/2 mutated better prognosis with inhibitors, OS +6 months
Verified19APL subtype 90% curable with ATRA+ATO
Directional20Elderly unfit median OS 3-5 months BSC
Single source21HSCT in CR1 improves 3-year OS 55% vs 35% chemo
Verified22RUNX1 mutated: median OS 12 months
Verified23Overall 5-year survival improved from 24% to 30% 2013-2019
Verified24t(8;21) favorable: 70% 5-year EFS
Directional25ASXL1 mutation worsens prognosis, HR=1.8
Single source26Relapsed AML median OS 4-6 months
Verified27MRD+ post-consolidation: relapse risk 50-80%
VerifiedSurvival Rates and Prognosis Interpretation
Even with a five-year survival rate that can feel like a cruel roll of the dice—from a bleak 4% to a hopeful 90%—your specific genetics, age, and response to treatment ultimately write your personal prognosis, for better or worse.
Symptoms and Diagnosis
1Fatigue is the most common symptom in 90% of AML patients
Verified2Anemia present at diagnosis in 85-90% of cases
Verified3Bone marrow blasts ≥20% defines AML diagnosis
Verified4Thrombocytopenia in 70-80% at presentation
Directional5Flow cytometry detects abnormal myeloid markers in 95% accuracy
Single source6Fever/infection in 50-60% due to neutropenia
Verified7Cytogenetic analysis prognostic in 90% of cases
Verified8Easy bruising/bleeding in 50% of patients
Verified9Leukocytosis >100,000 in 20% hyperleukocytosis cases
Directional10Bone pain reported in 25-40% of patients
Single source11PET/CT sensitivity for extramedullary disease 80%
Verified12Gum hypertrophy in monocytic AML (FAB M4/M5) 20-40%
Verified13Molecular testing for NPM1 in 30-35% favorable cases
Verified14Shortness of breath from anemia in 60%
Directional15Splenomegaly in 20-30% at diagnosis
Single source16Next-gen sequencing detects mutations in 90% AML
Verified17Weight loss/unintentional in 20%
Verified18Lymphadenopathy rare, <10%
Verified19HLA typing for transplant in 100% eligible patients
Directional20Skin involvement (leukemia cutis) in 10-15% M4/M5
Single source21Median WBC at diagnosis 15,000-100,000/uL
Verified22MRD assessment by flow in 70-80% sensitivity post-induction
Verified23Gingival bleeding common in thrombocytopenia
Verified24Hepatomegaly in 10-20%
Directional25FLT3-ITD mutation testing in all patients
Single source26Night sweats in 25%
Verified27Central nervous system involvement <5%
Verified28Complete remission defined as <5% blasts
VerifiedSymptoms and Diagnosis Interpretation
AML is a brutal arithmetic where the most common symptom is the exhaustion of fighting it, nearly everyone is anemic at diagnosis while blast counts define the war, and though the disease loudly announces itself through bleeding, fever, and pain, our most critical weapons—from cytogenetics to sequencing—are the precise intelligence gathering that makes remission a target we can actually hit.
Treatment and Outcomes
1Induction chemotherapy CR rate 60-80% in young patients
Verified27+3 regimen (cytarabine + daunorubicin) standard for fit patients
Verified3Venetoclax + HMA CR/CRi 67% in unfit elderly
Verified4Allogeneic HSCT relapse rate 30-50% at 2 years
Directional5Midostaurin improves OS in FLT3-mutated AML by 22%
Single source6Gemtuzumab ozogamicin OS benefit 15% in favorable risk
Verified7CPX-351 CR 48% vs 33% in secondary AML
Verified8Azacitidine median OS 10.4 months in unfit patients
Verified9Quizartinib PFS 8.5 months in FLT3-ITD relapsed
Directional10Intensive chemo mortality 1-5% induction
Single source11HMA + venetoclax OS 14.7 months unfit elderly
Verified12Auto-HSCT used rarely, <10% AML patients
Verified13Ivosidenib ORR 42% IDH1-mutated relapsed
Verified14Enasidenib ORR 40% IDH2-mutated relapsed
Directional15Glasdegib + LDAC OS 8.8 vs 4.5 months
Single source16CAR-T limited data, response in 50-70% refractory
Verified17Maintenance azacitidine post-HSCT reduces relapse 30%
Verified18CRp rate with HMA alone 20-30% unfit
Verified19Targeted therapy access improved outcomes 20% since 2017
Directional20Relapse occurs in 50-70% after first CR
Single source21Hypomethylating agents used in 40% newly diagnosed unfit
Verified22HSCT in first CR: 50-60% LFS favorable risk
Verified23Oral azacitidine maintenance PFS doubled
Verified24Gilteritinib ORR 52% FLT3 relapsed/refractory
Directional25Intensive therapy CR 70% under 60 years
Single source26Supportive care: platelet transfusion threshold 10,000/uL
VerifiedTreatment and Outcomes Interpretation
We have become adept at threading a therapeutic needle, balancing hopeful remission rates against sobering relapse risks, all while an expanding arsenal of targeted agents slowly reshapes the odds for patients both young and old.
Sources & References
- Reference 1CANCERcancer.govVisit source
- Reference 2CANCERcancer.orgVisit source
- Reference 3SEERseer.cancer.govVisit source
- Reference 4LLSlls.orgVisit source
- Reference 5NCBIncbi.nlm.nih.govVisit source
- Reference 6MAYOCLINICmayoclinic.orgVisit source
- Reference 7PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 8MSKCCmskcc.orgVisit source
- Reference 9NEJMnejm.orgVisit source